Publications
Specialty
Search
ePlasty, Surgery
09/16/2024
This study compares barbed versus smooth sutures for capsulorrhaphy in breast reconstruction, focusing on safety, efficiency, and outcomes.
ePlasty
09/16/2024
This review assessed ChatGPT's role in plastic surgery, focusing on research generation, medical literature summarization, and patient consultation capabilities.
EP Lab Digest
09/16/2024
BIOTRONIK Press Release
Vascular Disease Management, CardioVascular
09/16/2024
Watch as Mary Yost, MBA, cofounder of The Yost Group, discusses her AMP 2024 presentation on the consequences of amputation as a treatment for patients with critical limb ischemia.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular, Vascular Disease Management
09/16/2024
The Shockwave E8 catheter is designed to optimize the treatment of patients with calcified femoro-popliteal and below-the-knee peripheral artery disease (PAD), including patients with complex chronic limb-threatening ischemia (CLTI).
Vascular Disease Management, CardioVascular
09/16/2024
PLANO, Texas, Sept. 16, 2024 /PRNewswire/ -- Argon Medical Devices, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the launch of the CLEANER Vac™ Thrombectomy System for the removal of blood clot from the peripheral venous vasculature.
Oncology
09/16/2024
Sheela Rao, MBBS, MD, discusses results from the phase 3 POD1UM-303/InterAACT 2 study which showed encouraging efficacy with retifanlimab added to standard of care chemotherapy in patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Oncology
09/16/2024
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Oncology
09/16/2024
Results from the phase 2 GALAXIES Lung-201 study show the addition of berlrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.
Oncology
09/15/2024
The NIAGARA trial showed that durvalumab plus neoadjuvant chemotherapy improved EFS and OS compared to neoadjuvant chemotherapy alone in patients with muscle-invasive bladder cancer.
Oncology
09/15/2024
The KEYNOTE-522 trial demonstrated a statistically significant and clinically meaningful improvement in OS with the addition of pembrolizumab to neoadjuvant chemotherapy for patients with high-risk, early-stage triple-negative breast cancer.
Oncology
09/15/2024
Results from the phase 3 HypoG-01 trial show hypofractionated locoregional radiation therapy is non-inferior to normofractionated radiation therapy in terms of arm lymphedema risk in early breast cancer and did not lead to unfavorable study outcomes.
Oncology
09/15/2024
Peter Schmid, MD, PhD, discusses results from the phase 3 KEYNOTE-522 study which demonstrated significantly improved overall survival with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for patients with high-risk, early-stage triple-negative breast cancer.
Oncology
09/15/2024
Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in HR-positive, HER2-positive early breast cancer.
Oncology
09/14/2024
Pembrolizumab plus chemoradiotherapy significantly improves OS compared to placebo plus chemoradiotherapy in patients with high-risk, locally advanced cervical cancer, according to a second interim analysis from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
Oncology, IO Learning
09/14/2024
The LEAP-012 trial met its primary end point demonstrating a statistically significant and clinically meaningful improvement in PFS with the addition of lenvatinib plus pembrolizumab to TACE for patients with intermediate-stage hepatocellular carcinoma.
Oncology
09/14/2024
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Oncology
09/14/2024
Findings from the phase 3 PEACE-3 trial demonstrate the addition of 6 cycles of Ra223 to enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer significantly improves radiological PFS vs enzalutamide alone.
Oncology
09/14/2024
Lothar Bergmann, MD, discusses results from the phase 2 SUNNIFORECAST trial which assessed the efficacy of combination immunotherapy in patients with advanced non-clear cell renal cancers.